Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 16/2013

01.11.2013 | R&D Insight Report

Olodaterol: First Global Approval

verfasst von: Andrew Gibb, Lily P. H. Yang

Erschienen in: Drugs | Ausgabe 16/2013

Einloggen, um Zugang zu erhalten

Abstract

Olodaterol (Striverdi® Respimat®) is a novel, long-acting, β2-adrenergic receptor agonist developed by Boehringer Ingelheim for the treatment of chronic obstructive pulmonary disease (COPD). The drug is delivered via the Respimat® Soft Mist™ inhaler. Olodaterol received its first global approval for the once-daily maintenance treatment of COPD in Canada and Russia, and submissions for regulatory approval have also been made in the USA, the EU and elsewhere. Phase II trials have been conducted in patients with asthma. The company is also developing a fixed-dose combination of olodaterol with tiotropium bromide, a long-acting anti-muscarinic agent, for the treatment of COPD. This article summarizes the milestones in the development of olodaterol leading to this first approval for COPD.
Literatur
1.
Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–65.PubMedCrossRef
2.
Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64(3):450–504.PubMedCrossRef
3.
4.
Joos G, Aumann JL, Coeck C, et al. Comparison of 24-hour FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting B2-agonist, in patients with COPD [abstract no. A2930]. Am J Respir Crit Care Med. 2012;185(Abstract issue).
5.
Bouyssou T, Casarosa P, Naline E, et al. Pharmacological characterization of olodaterol, a novel inhaled β2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther. 2010;334(1):53–62.PubMedCrossRef
6.
Brown SM, Barnes PJ, Donnelly LE. Effect of olodaterol on the relaxation of small airways [abstract]. 2011 Annual Congress of the European Respiratory Society; 24–28 Sep 2011; Amsterdam.
7.
Lamyel F, Warnken-Uhlich M, Seemann WK, et al. The β2-subtype of adrenoceptors mediates inhibition of pro-fibrotic events in human lung fibroblasts. Naunyn-Schmiedeberg’s Arch Pharmacol. 2011;384(2):133–45.CrossRef
8.
Racké K, Warnken M, Ahmedat AS, et al. The long acting beta2-adrenoceptor agonist olodaterol mediates inhibition of prepro-endothelin-1 expression in human lung fibroblasts [abstract no. A6053]. Am J Respir Crit Care Med. 2011;183(Abstracts issue).
9.
Lewis R, Chachi Y, Amrani P. A comparison of B2-adrenoceptor desensitisation induced by olodaterol and formoterol in human lung mast cells and airway smooth muscle cells [abstract no. P1589]. 2013 Annual Congress of the European Respiratory Society; 7–11 Sep 2013; Barcelona.
10.
Naline E, Ostermann A, Devillier P, et al. β2 agonist intrinsic activity: comparison of BI 1744 and formoterol in different functional settings [abstract no. A4443]. Am J Respir Crit Care Med. 2010;181(Abstracts issue).
11.
Casarosa P, Kollak I, Kiechle T, et al. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol. J Pharmacol Exp Ther. 2011;337(3):600–9.PubMedCrossRef
12.
van Noord JA, Smeets JJ, Drenth BM, et al. 24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPD. Pulm Pharmacol Ther. 2011;24(6):666–72.PubMedCrossRef
13.
O’Byrne PM, van der Linde J, Cockcroft DW, et al. Prolonged bronchoprotection against inhaled methacholine by inhaled BI 1744, along-acting beta(2)-agonist, in patients with mild asthma. J Allergy Clin Immunol. 2009;124:1217–21.PubMedCrossRef
14.
van Noord JA, Korducki L, Hamilton AL. Four weeks once daily treatment with BI 1744 CL, a novel long-acting beta-2-agonist, is effective in COPD patients [abstract no. A6183]. Am J Respir Crit Care Med. 2009;179(Abstracts issue).
15.
Troost J, Pivovarova A, Kunz C, et al. Evaluation of the effects of the long-acting β2-agonist olodaterol on the Qt and Qtc interval in healthy subjects [abstract no. A2603]. Am J Respir Crit Care Med. 2013;187(Abstracts issue).
16.
Profita M, Albano GD, Montalbano AM, et al. Acetylcholine leads to signal transducer and activator of transcription 1 (STAT-1) mediated oxidative/nitrosative stress in human bronchial epithelial cell line. Biochim Biophys Acta Mol Basis Dis. 2013;1832(12):1949–58.CrossRef
17.
Profita M, Bonanno A, Montalbano AM, et al. β2 long-acting and anticholinergic drugs control TGF-β1-mediated neutrophilic inflammation in COPD. Biochim Biophys Acta. 2012;1822(7):1079–89.PubMedCrossRef
18.
Bouyssou T, Schnapp A, Casarosa P, et al. Addition of the new once-daily LABA BI 1744 to tiotropium results in superior bronchoprotection in pre-clinical models [abstract no. A4448]. Am J Respir Crit Care Med. 2010;181(Abstracts issue).
19.
Schlepütz M, Maihöfer N, Rieg AD, et al. Combination study of tiotropium and olodaterol in human precision-cut lung slices [abstract]. 2013 Annual Congress of the European Respiratory Society; 7–11 Sep 2013; Barcelona.
20.
Meurs H, Smit M, Zuidhof AB, et al. The bronchoprotective effect of olodaterol against histamine is synergistically enhanced and prolonged by tiotropium bromide [abstract no. A1379]. Am J Respir Crit Care Med. 2011;183(Abstracts issue).
21.
Smit M, Zuidhof A, Bos S, et al. Protection against allergen-induced airway hyperresponsiveness (AHR) by olodaterol in guinea pigs is synergistically enhanced by tiotropium [abstract]. 2012 Annual Congress of the European Respiratory Society; 1–5 Sep 2012; Vienna.
22.
Smit M, Zuidhof AB, Bos IST, et al. Acute reversal of allergen-induced airway hyperresponsiveness (AHR) by olodaterol is synergistically enhanced by tiotropium bromide [abstract]. 2011 Annual Congress of the European Respiratory Society; 24–28 Sep 2011; Amsterdam.
23.
Costa L, Roth M, Tamm M, et al. Tiotropium enhances the inhibitory effect of the long acting β2-agonist olodaterol on the release of IL-6 and IL8 by primary human lung fibroblasts of asthma patients [abstract]. 2012 Annual Congress of the European Respiratory Society; 1–5 Sep 2012; Vienna.
24.
Costa L, Roth M, Tamm M, et al. Tiotropium and olodaterol exert anti-proliferative effects on pulmonary fibroblasts of asthmatic patients in vitro [abstract no. P571]. 2013 Annual Congress of the European Respiratory Society; 7–11 Sep 2013; Barcelona.
25.
Bouyssou T, Casarosa P, Pieper M, et al. Synergistic bronchoprotective activity of the long-acting beta 2-agonist olodaterol with tiotropium (long-acting M3 antagonist) and ciclesonide (inhaled steroid) on the ovalbumin-induced bronchoconstriction in anaesthetized guinea pigs [abstract]. 2011 Annual Congress of the European Respiratory Society; 24–28 Sep 2011; Amsterdam.
26.
Ferguson G, Feldman G, Hofbauer P, et al. Lung function efficacy of olodaterol QD delivered via Respimat® in COPD patients: results from two 48-week studies [abstract no. 187]. 2013 Annual Congress of the European Respiratory Society; 7–11 Sep 2013; Barcelona.
27.
Koch A, Pizzichini E, Hamilton A, et al. Lung function efficacy of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: two 48-week studies [abstract no. P764 plus poster]. 2013 Annual Congress of the European Respiratory Society; 7–11 Sep 2013; Barcelona.
28.
Koch A, Paggiaro P, Hamilton A, et al. Symptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: combined analysis from two 48-week studies [abstract no. P763]. 2013 Annual Congress of the European Respiratory Society; 7–11 Sep 2013; Barcelona.
29.
30.
Lange P, Aumann JL, Derom E, et al. The 24-h FEV1 time profile of olodaterol QD delivered via Respimat® in COPD: results from two 6-week studies [abstract no. 4635]. 2013 Annual Congress of the European Respiratory Society; 7–11 Sep 2013; Barcelona.
31.
Ichinose M, Takizawa A, Izumoto T. Efficacy of 4 weeks’ once-daily treatment with olodaterol (BI 1744), a novel long-acting B2-agonist, in Japanese patients with COPD [abstract no. A2931]. Am J Respir Crit Care Med. 2012;185(Abstract issue).
32.
33.
Beeh KM, Beck E, Gahlemann M, et al. Dose-finding study of 4-week, once-daily treatment with olodaterol, a novel long-acting B2-agonist, in patients with asthma [abstract no. A2764]. Am J Respir Crit Care Med. 2012;185(Abstract issue).
34.
O’Byrne PM, D’Urzo T, Gahlemann M, et al. Dose-finding study of once-daily treatment with olodaterol, a novel long-acting B2-agonist, in patients with asthma [abstract no. A3963]. Am J Respir Crit Care Med. 2012;185(Abstract issue).
35.
36.
Aalbers R, Maleki-Yazdi MR, Hamilton A, et al. Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD [abstract no. P2882]. 22nd Annual Congress of the European Respiratory Society; 1–5 Sep 2012; Vienna.
37.
Maltais F, Beck E, Webster D, et al. Four weeks once daily treatment with tiotropium + olodaterol (BI1744) fixed dose combination compared with tiotropium in COPD patients [abstract no. 5557]. 20th Annual Congress of the European Respiratory Society; 18–22 Sep 2013; Barcelona.
38.
Jenkins CR. More than just reassurance on tiotropium safety. N Engl J Med. 2013;369(16):1555–6.
39.
Wise RA, Anzueto A, Cotton D, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369(16):1491–501.
40.
McGarvey L, Koch A, Sachs P, et al. 48-week administration of olodaterol QD via Respimat® vs placebo and formoterol BID in patients with COPD: pooled safety analysis [abstract no. P3633]. 2013 Annual Congress of the European Respiratory Society; 7–11 Sep 2013; Barcelona.
41.
Metadaten
Titel
Olodaterol: First Global Approval
verfasst von
Andrew Gibb
Lily P. H. Yang
Publikationsdatum
01.11.2013
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 16/2013
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-013-0137-9

Weitere Artikel der Ausgabe 16/2013

Drugs 16/2013 Zur Ausgabe

Adis Drug Evaluation

Telavancin: A Review of Its Use in Patients with Nosocomial Pneumonia

Current Opinion

Preventing Postoperative Recurrence in Crohn’s Disease: What Does the Future Hold?

Therapy in Practice

Current Management of Iron Deficiency Anemia in Inflammatory Bowel Diseases: A Practical Guide

Adis Drug Evaluation

Tobramycin Inhalation Powder: A Review of Its Use in the Treatment of Chronic Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis

Erratum

Erratum to: Canagliflozin: First Global Approval

Review Article

Current and Emerging Options for the Drug Treatment of Narcolepsy